Mitocryptide-2: Identification of Its Minimum Structure for Specific Activation of FPR2-Possible Receptor Switching from FPR2 to FPR1 by Its Physiological C-terminal Cleavages.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
15 Apr 2021
Historique:
received: 02 03 2021
revised: 02 04 2021
accepted: 12 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 14 5 2021
Statut: epublish

Résumé

Mitocryptides are a novel family of endogenous neutrophil-activating peptides originating from various mitochondrial proteins. Mitocryptide-2 (MCT-2) is one of such neutrophil-activating peptides, and is produced as an N-formylated pentadecapeptide from mitochondrial cytochrome

Identifiants

pubmed: 33920954
pii: ijms22084084
doi: 10.3390/ijms22084084
pmc: PMC8071274
pii:
doi:

Substances chimiques

FPR1 protein, human 0
FPR2 protein, human 0
Peptides 0
Receptors, Formyl Peptide 0
Receptors, Lipoxin 0
beta-N-Acetylhexosaminidases EC 3.2.1.52
Calcium SY7Q814VUP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 19K05853
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 17J11507

Références

Am J Physiol. 1987 Jun;252(6 Pt 1):E765-71
pubmed: 3109252
Nat Rev Immunol. 2013 Mar;13(3):159-75
pubmed: 23435331
J Immunol. 1978 Jan;120(1):109-15
pubmed: 342601
PLoS One. 2015 Oct 09;10(10):e0140105
pubmed: 26451593
J Biol Chem. 1995 Jun 23;270(25):15175-80
pubmed: 7797501
J Clin Invest. 1989 Oct;84(4):1045-9
pubmed: 2677047
J Exp Med. 1972 Feb 1;135(2):376-87
pubmed: 4551218
J Immunol. 2010 Oct 1;185(7):4302-10
pubmed: 20817875
J Orthop Trauma. 2010 Sep;24(9):534-8
pubmed: 20736789
PLoS Med. 2013 Dec;10(12):e1001577; discussion e1001577
pubmed: 24391478
Circ Res. 2016 Jun 10;118(12):1960-91
pubmed: 27126807
Biochem Biophys Res Commun. 1987 Dec 16;149(2):755-61
pubmed: 3322281
Protein Pept Lett. 2012 Jun 1;19(6):680-7
pubmed: 22519541
J Immunol. 2009 Apr 15;182(8):5072-80
pubmed: 19342687
Ann Neurol. 2013 Nov;74(5):655-68
pubmed: 23794434
J Immunol. 2019 May 1;202(9):2710-2719
pubmed: 30902901
Cell Death Dis. 2014 Jul 03;5:e1312
pubmed: 24991764
Sci Rep. 2019 May 2;9(1):6815
pubmed: 31048743
Nat Commun. 2020 Feb 14;11(1):885
pubmed: 32060286
Trends Immunol. 2018 Oct;39(10):815-829
pubmed: 30195466
Biopolymers. 2016 Nov 4;106(4):580-7
pubmed: 26600263
Biochem Biophys Res Commun. 1990 May 16;168(3):1103-9
pubmed: 2161213
Cell. 1994 Jan 28;76(2):301-14
pubmed: 7507411
Proc Natl Acad Sci U S A. 1986 Aug;83(16):5774-8
pubmed: 2874556
Biochem Pharmacol. 2016 Aug 15;114:22-39
pubmed: 27131862
Exp Mol Med. 2013 Sep 13;45:e40
pubmed: 24030327
Hepatol Res. 2013 May;43(5):526-34
pubmed: 22971177
Biochem J. 1992 Dec 15;288 ( Pt 3):1025-35
pubmed: 1281979
PLoS One. 2014 Mar 06;9(6):e90613
pubmed: 24603667
Biopolymers. 2007;88(2):190-8
pubmed: 17245751
Invest Ophthalmol Vis Sci. 2011 May 16;52(6):3160-5
pubmed: 21228377
Proc Natl Acad Sci U S A. 1980 Feb;77(2):1000-4
pubmed: 6928654
Injury. 2015;46(6):975-84
pubmed: 25817163
Oncoimmunology. 2015 Aug 24;5(2):e1078055
pubmed: 27057451
Science. 2010 Oct 15;330(6002):362-6
pubmed: 20947763
Am J Respir Cell Mol Biol. 2011 Mar;44(3):264-9
pubmed: 20889801
J Clin Invest. 1982 Nov;70(5):953-64
pubmed: 6290539
J Biol Chem. 2008 Nov 7;283(45):30596-605
pubmed: 18768476
Annu Rev Immunol. 1994;12:593-633
pubmed: 8011292
Front Immunol. 2017 Apr 26;8:508
pubmed: 28491064
Immunity. 2015 Mar 17;42(3):406-17
pubmed: 25786173
Cardiovasc Res. 1996 Oct;32(4):733-42
pubmed: 8915191
Biochem Biophys Res Commun. 2007 Oct 12;362(1):51-55
pubmed: 17692824
J Biol Chem. 1993 Aug 25;268(24):18167-75
pubmed: 8349692
Methods Enzymol. 2009;456:111-31
pubmed: 19348885
J Immunol. 2018 May 1;200(9):3269-3282
pubmed: 29602776
Biochem Biophys Res Commun. 2011 Jan 7;404(1):482-7
pubmed: 21144840
Proc Natl Acad Sci U S A. 1977 Mar;74(3):1204-8
pubmed: 265563
J Biol Chem. 1984 May 10;259(9):5430-9
pubmed: 6371005
Int J Mol Sci. 2016 Aug 30;17(9):
pubmed: 27589725
J Immunol. 2007 Dec 15;179(12):8112-21
pubmed: 18056353
PLoS One. 2012;7(12):e49767
pubmed: 23284625
J Biol Chem. 1992 Aug 15;267(23):16237-43
pubmed: 1379592
Front Immunol. 2018 May 04;9:832
pubmed: 29780380
Am J Physiol Heart Circ Physiol. 2015 Apr 1;308(7):H768-77
pubmed: 25637548
Biochemistry. 1984 Apr 10;23(8):1811-8
pubmed: 6326812
J Immunol. 2010 Mar 1;184(5):2611-2619
pubmed: 20107188
Int J Mol Med. 2017 Oct;40(4):1261-1269
pubmed: 28849179
Proc Natl Acad Sci U S A. 1975 Mar;72(3):1059-62
pubmed: 1093163
Nature. 2010 Mar 4;464(7285):104-7
pubmed: 20203610
Annu Rev Biochem. 2016 Jun 2;85:77-101
pubmed: 26789594

Auteurs

Takayuki Marutani (T)

Laboratory of Peptide Science, Graduate School of Bio-Science, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga 526-0829, Japan.

Kodai Nishino (K)

Laboratory of Peptide Science, Graduate School of Bio-Science, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga 526-0829, Japan.

Tomoyuki Miyaji (T)

Laboratory of Peptide Science, Graduate School of Bio-Science, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga 526-0829, Japan.

Keisuke Kamada (K)

Laboratory of Peptide Science, Graduate School of Bio-Science, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga 526-0829, Japan.

Koji Ohura (K)

Laboratory of Peptide Science, Graduate School of Bio-Science, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga 526-0829, Japan.

Yoshiaki Kiso (Y)

Laboratory of Peptide Science, Graduate School of Bio-Science, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga 526-0829, Japan.

Hidehito Mukai (H)

Laboratory of Peptide Science, Graduate School of Bio-Science, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga 526-0829, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH